Skip to main content
UAB - The University of Alabama at Birmingham
admin login frontend login
Canine Immunoneurotherapeutics Trial
Heersink School of Medicine
  • UAB Quicklinks
      • UAB Home
      • Academic Calendar
      • Accessibility
      • AdminSystems
      • Apply
      • AskIT
      • Blazer Express
      • BlazerNET
      • BlazerPulse
      • Bookstore
      • Campus Calendar
      • Campus Map
      • Canvas
      • Departments
      • Directory
      • Email
      • Emergency/B-Alert
      • Employee Resources
      • Employment
      • MyUAB Employee Portal
      • Giving to UAB
      • TechConnect
      • UAB eLearning
      More Items
 
  • About
  • Research
  • Investigators
  • News
  • Contact
Portrait of happy family enjoying in park on sunny a day

People share many things with the dogs in their lives. Unfortunately, that can include a tendency to develop brain tumors.

The biological similarities between humans and dogs are far more significant than the differences. We share more than our lives with our pets – we share our living space, our air, our recreational activities and sometimes our food. One Medicine is the concept that veterinary in human medicines often overlap and that each can learn from the other to the benefit of both.

Our Canine Immunoneurotherapeutics Trial, or CANINE, has received funding from the National Institutes of Health to use human therapies to treat and study canine brain tumors. Interestingly, dogs and humans develop malignant brain tumors at about the same rate, and these tumors are biologically similar. A trial like this allows us to provide compassionate care to animals, advance the field of veterinary medicine and better understand the biological effects of treatment. Discovering what we have in common may just lead to a cure.

Please review the information on this site to determine if our trial is right for you and your pet. Veterinarians may contact any of the regional study sites for more information regarding referrals.

Dogs and humans develop malignant brain tumors at about the same rate and with similar biology.

Dogs and humans develop malignant brain tumors at about the same rate and with similar biology.

Learn more

The current phase of this trial will establish the maximum safe and effective dose of M032, the FDA-approved, clinical-grade oncolytic herpes simplex virus that expresses an IL-12.

The current phase of this trial will establish the maximum safe and effective dose of M032, the FDA-approved, clinical-grade oncolytic herpes simplex virus that expresses an IL-12.

Learn more

Home

In the News

  • UAB News

    Brain tumor therapy is going to the dogs

    Read more

  • American Veterinarian

    Cancer immunotherapy developed for humans will be used to treat dogs

    Read more

  • WBRC

    UAB study could help save dogs, humans with brain tumors

    Read more

  • WVTM

    UAB study could help save dogs, humans with brain tumors

    Read more

  • UAB Magazine

    How dogs could help humans fight cancer – and vice versa

    Read more

  • AVMA

    Mississippi State’s specialty center shares advanced equipment with human medical practice

    Read more

  • AU College of Veterinary Medicine

    Auburn Veterinary Medicine, UAB part of joint NIH study of glioma brain cancer

    Read more

  • UAB Medcast

    Brain tumor therapy is going to the dogs

    Read more

  • NCI/DCTD

    NCI-funded canine immunotherapy trials network treats pet dogs to study cancers common to humans

    Read more

  • WIRED

    Why dogs now play a big role in human cancer research

    Read more

 
Research reported in this webpage is supported by the National Cancer Institute of the National Institutes of Health under Award Number U01CA224151. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
  • Contact UAB
  • |
  • |
  • A-Z Site Index
  • |
  • Privacy
  • |
  • Terms of Use
  • |
  • © 2023 The University of Alabama at Birmingham
UAB is an Equal Opportunity/Affirmative Action Employer committed to fostering a diverse, equitable and family-friendly environment in which all faculty and staff can excel and achieve work/life balance irrespective of race, national origin, age, genetic or family medical history, gender, faith, gender identity and expression as well as sexual orientation. UAB also encourages applications from individuals with disabilities and veterans.